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The clinical eﬃcacy of the Chinese therapeutic food (speciﬁcally hawthorn fruit and Chinese kiwifruit-extract compound) on
dyslipidemiawasevaluatedinthisplacebo-controlled,doubleblind,pairedclinicaltrialconductedinMelbourne,Australia.Forty-
three participants diagnosed with moderate dyslipidemia and met the study criteria were randomly assigned to Group A or B,
with baseline characteristics matched. Twenty-seven participants completed all the tests, the blood lipid proﬁle including total
cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and triglycerides
(TG) was analysed. The traditional Chinese medicine diagnosis was made based on participants’ symptoms and signs. The results
indicate that a four-week intake of the compound increased the serum HDL-c levels by 5% (P = 0.026) and decreased the ratios
of TC/HDL-c and LDL-c/HDL-c (P = 0.012 and P = 0.044, resp.). The placebo intake did not signiﬁcantly change the blood
lipid proﬁle. In the initial 43 participants with dyslipidemia, 76.7% of them were diagnosed with “Spleen deﬁciency” and 58.1%
with “Liver qi stagnation.” The intake of hawthorn fruit and Chinese kiwifruit extract compound may increase the serum levels of
HDL-c and decrease the ratios of TC/HDL-c and LDL-c/HDL-c, therefore, may reduce the risk of cardiovascular disease.
1.Introduction
Atherosclerosis and subsequent cardiovascular disease
(CVD)arecommonandhavehighmortality.Dyslipidemiais
considered to be responsible for the development of ather-
osclerosis through blood lipid accumulation and oxidation
[1, 2]. The atherogenic lipid proﬁle includes increased low-
density lipoprotein cholesterol (LDL-c), triglycerides (TG),
and decreased high-density lipoprotein cholesterol (HDL-c),
which are all recognized as independent risk factors for
CVD. Therapeutic lifestyle changes are recommended as
the ﬁrst choice for blood lipid management, and dietary
intake is suggested to include reduced intake of saturated
fat and increased LDL-c lowering nutrients [3]. HMG-
CoA reductase inhibitors (statins), bile acid sequestrants,
nicotinic acid, and ﬁbric acids, are conventionally employed
to achieve diﬀerent goals of blood lipid management.
However, side eﬀects of the agents, such as myopathy and
increased liver enzymes [4], are a concern to users and
clinicians.
Chinese therapeutic food may make a valuable contribu-
tion to a more balanced diet. They have been used widely
with acknowledged safety in Chinese history, and recipes
based on herbal dietary therapy are accepted extensively
nowadays for the prevention and treatment of heart diseases
[5]. Chinese people have traditionally preferred food and
herbs to drugs for health care, and many herbs are described
asboth foodandmedicine bytheChinese Ministry ofHealth
[6]. In the selected therapeutic food supplement, hawthorn
fruit (Shan Zha) is known in traditional Chinese medicine
(TCM) for its eﬀects on reducing food stagnancy and blood
stasis.Asherbalmedicine,itisalsousedtotreatdyslipidemia,
angina pectoris, and hypertension [7]. Chinese kiwifruit
(Z h o n gH u aM iH o uT a o ) originated from China and its var-
ious cultivars have been widely consumed globally. Previous
studieshaveshownthattheChinesekiwifruitcultivarusedin2 Evidence-Based Complementary and Alternative Medicine
the supplement for this study appears to be antiatherogenic
[8, 9].
This study evaluated the eﬃcacy of the selected Chinese
therapeutic food supplement for the treatment of dyslipi-
demia in Australia and compared the outcomes with the
previous study conducted in China [10].
2. Methods
2.1. General Description. A placebo-controlled, double-
blind, paired research design was used in the present study,
based upon a previous study with positive outcomes [10].
Amongthe62applicants,43Australianparticipantswhomet
the inclusive criteria were recruited and assigned into two
groups. Two interventions, the therapeutic food compound
and the placebo, were applied in this study. The intervention
in the two groups was swapped at the middle of the study.
Before and after each period of intervention, fasting blood
samples were taken and analysed for the serum lipid levels.
Participants were also assessed from the TCM perspective.
This study was approved by the Human Research Ethics
Committee of Victoria University, Melbourne, Australia. It
was registered with the Australian-New Zealand Clinical
TrialsRegistry.TheTherapeuticFoodAdministration(TGA)
was notiﬁed of this trial.
In this present study, the heavy metal contents in
the compound were analysed by the Australian National
Measurement Institute and were found to be safe for
human consumption. The pesticide concentrations of the
supplements used in this study were also analysed at Victoria
University and found to be safe for human consumption.
2.2. Participants. All participants met the following criteria
before enrollment:
(i) have lived in Australia for the past 10 years,
(ii) diagnosedwithmoderatedyslipidemia,inwhichfast-
ing serum LDL-c level within 3.2–4.6mmol/L (125–
180mg/dL)orTG2.0–2.9mmol/L(180–250mg/dL),
according to Adult Treatment Panel III [3],
(iii) aged 40–70 years and with blood pressure lower than
159/99mmHg (A meta-analysis indicated that older
age and increasing blood pressure could attenuate
the proportional CVD risk reduction of cholesterol
lowering [11]; a similar clinical trial to evaluate the
eﬀects of berry consumption on CVD risk factors,
using “140–159mmHg systolic blood pressure or
90–99mmHg diastolic blood pressure” as inclusive
criteria for blood pressure, has shown favourable
outcomes [12]),
(iv) absence of other major medical conditions (i.e.,
established CVD, severe diabetes, thyroid dysfunc-
tion, asthma, hepatic or renal disorders) or preg-
nancy,
(v) not have taken other supplements or medicine which
may inﬂuence blood lipid levels in the past 3 months,
(vi) not allergic to the extract of the therapeutic food or
wheat germ,
(vii) not have ﬂuid retention or severe diarrhoea (accord-
ing to the TCM theory, the nature of kiwifruit is con-
sidered as cool, which means that intake of kiwifruit
may give rise to or deteriorate ﬂuid retention for
people with very weak digestive system and cold
nature; hawthorn fruit may cause slight diarrhoea
due to its eﬀecton reducing food stagnancy, however,
it is unlikely occur in this study because kiwifruit’s
coolnaturecanbebalancedbyhawthornfruit’swarm
nature and the nourishing eﬀect of kiwifruit may
also balance the hawthorn fruit’s eﬀect of reducing
stagnancy).
This study purposely did not include participants with an
Eastern Asian cultural background as a similar study has
already been conducted in China [10]. It is considered the
people with an Eastern Asian background, such as Chinese,
Korean, and Japanese, who may share similar culture-
aﬀected life styles. Therefore, genetic factors, locality, and/or
cultural diﬀerences were taken into account in comparison
with the previous study.
Volunteersparticipatinginthisstudywererecruitedfrom
the staﬀ of Victoria University and residents from the local
community (Melbourne, Australia). They became aware of
this study through public e-mails within Victoria University,
posters at community health centers, local newspapers, and
word of mouth.
Theissuespertainingtothisresearchwerereinforcedand
explained by the researchers at each interview. The treatment
and control crossover procedure was clearly described and
explained to each participant. The participants were also
informed that they could withdraw from this study at any
time. Each participant signed the consent form prior to
recruitment. All records were kept secure and conﬁdential
and can only be accessed by the related researchers.
2.3. Study Design. Participants were assigned into pairs
according to the baseline blood lipid levels and demographic
characteristics(i.e.,ageandgender).Arandomnumbertable
was used for grouping the randomly allocated participants.
Participants in Group A received the treatment of the
supplement for the ﬁrst four weeks while participants in
Group B received the control supplement (placebo) during
thesameperiod.Forthesecondfourweeks,theinterventions
were switched, that is, Group B received the supplement
and Group A took placebo, to observe long-term treatment
eﬀects in Group A. The total duration of participation was
eight weeks. Three oﬃce visits were organised during the
study (at the beginning, mid and the end of the participa-
tion, resp.). Treatment eﬀects have been considered within
individual Group A and B, and also for the combination of
Group A + B.
A practitioner who was familiar with this type of clinical
trial was invited as the third party to label the treatment and
placebo powder (which were packed in the same container).
The powder was assigned to match the participants’ codes
and groups (i.e., A1, A2...,o rB 1 ,B 2 ...;n a m e sw e r ek e p t
conﬁdential). This practitioner was asked not to revealEvidence-Based Complementary and Alternative Medicine 3
Table 1: Participants’ general information.
#Group
(No)
Age∗
Mean ±SD Male Female LDL-c∗
Mean ±SD
Systolic blood
pressure∗(mmHg)
Mean ±SD
Diastolic blood
pressure∗ (mmHg)
Mean ±SD
A( n = 14) 56.00 ±7.09 5 9 4.01 ±0.60 125.1 ±13.47 7 .9 ±7.5
B( n = 13) 53.62 ±9.85 8 5 3.95 ±0.61 125.8 ±10.07 9 .9 ±7.3
#A :G r o u pA — t o o kH F C( t r e a t m e n t )f o rt h eﬁ r s tf o u rw e e k s ;t h e nt o o kt h ep l a c e b of o rt h es e c o n df o u rw e e k s ;B :G r o u pB — t o o kt h ep l a c e b of o rt h eﬁ r s tf o u r
weeks; then took the HFC for the second four weeks.
∗P>0.05.
Analysed 
test results) 
Analysed 
Allocation
Analysis
Followup
Randomly assigned to group A or B (double blind)
Excluded due to 
have other health 
due to change of 
Did not 
complete 
the ﬁnal 
test due to 
change of 
residence 
Withdrew due to 
other health 
Withdrew due to 
other health 
conditions/change 
Excluded due to 
have other health 
Assessed for eligibility (n = 62)
Enrollment (n = 43)
the ﬁrst four weeks (n = 21) treatment for the ﬁrst four
weeks (n = 22)
conditions (n = 5)
conditions (n = 3)
of residence (n = 4)
the second four
weeks (n = 17)
treatment for the second four
weeks (n = 17)
conditions (n = 3);
lifestyle (n = 1)
(n = 3)
(n = 14 for
the ﬁrst and
second test
results; n = 11
for the third
(n = 13)
Group B—Took placebo for Group A—Received HFC
Group A—Took placebo for Group B—Received HFC
Figure 1: Flow chart of participants through each stage of the trial.
relevant information to either researchers or participants
until the ﬁnal data analysis was completed.
Blood lipid levels can be aﬀected by lifestyle-related
factors and can ﬂuctuate over time without treatment.
All participants in both the treatment and control groups
were advised not to change their normal daily lifestyle
during the course of this study. Thus, they were asked
to complete a questionnaire as to record their diets and
physical activities for the ﬁrst and last three days in each
phase of their participation. The questionnaire allowed the
researchers to monitor the participants’ diet and physical
activity to determine whether there were signiﬁcant changes.
By completing the questionnaire, the participants were also
made aware of their habits and were reminded not to make
any changes during the study.
2.4. Intervention. Hawthorn fruit compound (HFC) with an
established safe and eﬀective dosage of 10g twice per day4 Evidence-Based Complementary and Alternative Medicine
Table 2: Comparison of HDL-c levels (mmol/L) between pre- and
post-HFC treatment.
Group (no) Pretreatment∗
Mean ±SD
Posttreatment∗∗
Mean ±SD
A( n = 14) 1.44 ± 0.33 1.53 ±0.42#
B( n = 13) 1.50 ± 0.42 1.54 ±0.48
A+B(n = 27) 1.47 ± 0.37 1.54 ±0.44##
#P = 0.09; ##P = 0.026.
∗Pretreatment: Group A—pre-HFC treatment; Group B—completed the
ﬁrst four weeks of the placebo intake and is to start HFC treatment, that is
Postplacebo value.
∗∗Posttreatment: Group A completed HFC treatment for the ﬁrst four
weeks, that is Preplacebo value; Group B completed the HFC treatment for
the second four weeks.
Table 3: Comparison of HDL-c levels (mmol/L) between pre- and
postplacebo intake.
Group (no) Preplacebo intake∗
Mean ±SD
Postplacebo intake∗∗
Mean ±SD
A( n = 11) 1.55 ±0.39
∗∗∗ 1.53 ±0.34
B( n = 13) 1.58 ±0.44 1.50 ±0.42
P>0.05.
∗Preplacebo intake: Group A completed HFC treatment for the ﬁrst four
weeks and started the placebo intake.
∗∗Postplacebo intake: Group A completed the placebo intake for the second
four weeks; Group B completed the placebo intake for the ﬁrst four weeks.
∗∗∗This value is diﬀerent from the value of Group A (n = 14) at
posttreatment (1.53 ± 0.42, Table 2) because three participants withdrew
f r o mt h et r i a l .E l e v e np a rt i c i p a n t si nG r o u pA( n = 11) completed their test.
[7, 10] was selected as the treatment supplement. The com-
pound includes Chinese therapeutic food extract hawthorn
fruit (Crataegus pinnatiﬁda Bge.) and Chinese kiwifruit
(Actinidia chinensis var. deliciosa). It contains the eﬀec-
tive components haw ﬂavone, triterpenoid, rutin, tartaric
acid, citric acid, crategeolic acid, ester, glucoside, analytical
lipid enzyme, carbohydrate, some saponins, polysaccharides,
multiple kinds of organic acids, isoﬂavones, and adequate
amounts of trace elements, for example, zinc (Zn) and
strontium (Sr). The placebo consists of wheat germ, food
dye, and citric acid, and sweetener was used as a control
supplement in the same dose. Both the treatment and
placebo drinking powder were provided by the supplier of
the previous study in China [7, 10]. Participants were asked
to mix the drinking powder (either treatment or placebo)
withwarmwater,andtotakethesupplementwithaninterval
ofminimumonehourafterfoodintake.Eachparticipantwas
asked to complete a checklist of everyday supplement intake
to monitor the progress.
2.5. Blood Lipid Test Parameters. Blood lipid levels including
TC, TG, and HDL-c were assayed during pre-, mid- (at the
end of 4th week), and posttreatment periods. The LDL-
c level was calculated using the Friedewald equation [13]:
LDL-c = TC-HDL-c−TG/2.2 (all values in mmol/L). The
ratios of TC/HDL-c and LDL-c/HDL-c were also investi-
gated.
Blood samples were taken in the Outpatient Department
of the appointed hospitals with Melbourne Health Shared
Pathology Service (MHSPS), including Royal Melbourne
Hospital, Footscray Western Hospital, and Sunshine Hos-
pital. All blood tests were performed in the Melbourne
Health Shared Pathology Laboratory by the appointed staﬀ.
Enzymatic and spectrophotometric methods were used for
the study assays. Participants were asked to fast 12 hours
before the blood sample collection.
2.6. Traditional Chinese Medicine Assessment. Participants’
symptominformationwascollectedusingthestandardTCM
diagnostic methods, including inspection, asking questions,
listening, smelling, and palpation. The occurrence of certain
symptoms and signs indicates certain patterns of dishar-
mony, which was determined at every visit of assessment.
2.7. Statistical Analysis. The data were analysed through
the application of paired t-test using a software program
SPSS 18.0 to determine the diﬀerences between pre- and
postinterventions, and P<0.05 was accepted as being
signiﬁcant.
3. Results
3.1. General Information. Twenty-seven of the 43 partici-
pants completed all the treatment and placebo intervention
applicable to this study in eight weeks (Table 1). There is no
signiﬁcant diﬀerence of age, gender, baseline serum LDL-
c levels, and blood pressure between the two groups at the
baseline level. In Group A, 11 participants completed all the
three blood tests; three participants did not complete the
third blood test. In Group B, 13 participants completed all
the tests. The participants who discontinued were aﬀected
by conditions not related to this study, such as moving to
places other than Melbourne, other health conditions, and
signiﬁcant lifestyle changes (Figure 1).
3.2. Serum High-Density Lipoprotein Cholesterol (HDL-c)
Levels. There is an increase of the HDL-c levels when
comparing the pre- and posttherapeutic food treatment in
Group A. However, the change is not statistically signiﬁcant
(P = 0.09).Whencombiningthetreatmentresultsfromboth
groups (Group A + B), it was found that the overall increase
of HDL-c is statistically signiﬁcant (P = 0.026, Table 2). This
indicates that the HFC intake can improve the HDL-c level.
If a larger sample size is used, the result is likely to be more
promising.
There was no signiﬁcant diﬀerence of the HDL-c levels
between pre- and postplacebo intake in either Group A or
Group B (Table 3), although a decreasing trend is observed.
This indicates that the placebo intake may not aﬀect the
HDL-c level signiﬁcantly in this study. It is noted that in
the participants of Group A, who had completed their HFC
treatment prior to placebo intake, the HDL-c levels appear
to decrease not as much as compared to the results of
the participants of Group B, who meanwhile took placeboEvidence-Based Complementary and Alternative Medicine 5
Table 4: Comparison of TC and TG levels (mmol/L) between pre- and post-HFC treatment.
Group (No) TC Pretreatment∗
Mean ±SD
TC Posttreatment∗∗
Mean ±SD
TG Pretreatment∗
Mean ±SD
TG Posttreatment∗∗
Mean ±SD
A( n = 14) 6.23 ±0.63 6.34 ±0.57 1.69 ±0.79 1.76 ±0.89
B( n = 13) 6.41 ±0.60 6.28 ±0.70 1.74 ±0.83 1.55 ±0.71
A+B(n = 27) 6.31 ±0.61 6.31 ±0.62 1.71 ±0.79 1.66 ±0.80
P>0.05.
∗Pretreatment: Group A—pre-HFC treatment; Group B—completed the ﬁrst four weeks of the placebo intake.
∗∗Posttreatment: Group A completed HFC treatment for the ﬁrst four weeks; Group B completed HFC treatment for the second four weeks.
Table 5: Comparison of TC and TG levels (mmol/L) between pre- and postplacebo intake.
Group (No) TC Preplacebo intake∗
Mean ±SD
TC Postplacebo intake∗∗
Mean ±SD
TG Preplacebo intake∗
Mean ±SD
TG Postplacebo intake∗∗
Mean ±SD
A( n = 11) 6.40 ±0.60 6.57 ±0.65 1.54 ±0.59 1.59 ±0.73
B( n = 13) 6.35 ±0.65 6.41 ±0.60 1.83 ±1.00 1.74 ±0.83
P>0.05.
∗Preplacebo intake: Group A completed HFC treatment for the ﬁrst four weeks and started the placebo intake.
∗∗Postplacebo intake: Group A completed the placebo intake for the second four weeks; Group B completed the placebo intake for the ﬁrst four weeks.
Table 6: Comparison of the TC/HDL-c ratio between pre- and
post-HFC treatment.
Group (No) Pretreatment∗ Posttreatment∗∗
Mean ±SD Mean ±SD
A( n = 14) 4.54 ±1.12 4.41 ±1.13
B( n = 13) 4.58 ±1.26 4.37 ±1.20#
A+B(n = 27) 4.56 ±1.17 4.39 ±1.14##
#P = 0.032; ##P = 0.012.
∗Pretreatment: Group A—pre-HFC treatment; Group B—completed the
ﬁrst four weeks of the placebo intake.
∗∗Posttreatment: Group A completed HFC treatment for the ﬁrst four
weeks; Group B completed HFC treatment for the second four weeks.
Table 7: Comparison of the TC/HDL-c ratio between pre- and
postplacebo intake.
Group (No) Preplacebo intake∗ Postplacebo intake∗∗
Mean ±SD Mean ±SD
A( n = 11) 4.29 ±0.80 4.44 ± 0.93#
B( n = 13) 4.31 ±1.20 4.58 ±1.26##
#P>0.05; ##P = 0.047.
∗Preplacebo intake: Group A completed HFC treatment for the ﬁrst four
weeks and started the placebo intake.
∗∗Postplacebo intake: Group A completed the placebo intake for the second
four weeks; Group B completed the placebo intake for the ﬁrst four weeks.
ﬁrst. Further research with more participants is required to
evaluate the long-term eﬀect of HFC on the HDL-c levels.
3.3. Serum Total Cholesterol (TC) and Triglycerides (TG).
Tables 4 and 5 show the eﬀects of either HFC or the placebo
on TC and TG are not statistically signiﬁcant (P>0.05).
3.4. The Ratio of Total Cholesterol and High-Density Lipopro-
tein Cholesterol (TC/HDL-c). Table 6 shows that there is a
signiﬁcant decrease of the TC/HDL-c ratio comparing the
Table 8: Comparison of LDL-c levels (mmol/L) between pre- and
post-HFC treatment.
Group (No) Pretreatment∗ Posttreatment∗∗
Mean ±SD Mean ±SD
A( n = 14) 4.01 ±0.60 4.03 ±0.43
B( n = 13) 4.10 ±0.50 4.02 ±0.63
A+B(n = 27) 4.06 ±0.55 4.02 ±0.53
P>0.05.
∗Pretreatment: Group A—pre-HFC treatment; Group B—completed the
ﬁrst four weeks of the placebo intake.
∗∗Posttreatment: Group A completed HFC treatment for the ﬁrst four
weeks; Group B completed HFC treatment for the second four weeks.
Table 9: Comparison of LDL-c levels (mmol/L) between pre- and
postplacebo intake.
Group (No) Preplacebo intake∗ Postplacebo intake∗∗
Mean ±SD Mean ±SD
A( n = 11) 4.17 ±0.33 4.32 ±0.50
B( n = 13) 3.95 ±0.61 4.10 ±0.50
P>0.05.
∗Preplacebo intake: Group A completed HFC treatment for the ﬁrst four
weeks and started the placebo intake.
∗∗Postplacebo intake: Group A completed the placebo intake for the second
four weeks; Group B completed the placebo intake for the ﬁrst four weeks.
pre- and posttreatment in Group B (P = 0.032) and in
Group A + B (P = 0.012). The results indicate that HFC
can eﬀectively lower the ratio of TC/HDL-c, an informative
marker of atherosclerosis.
There is an insigniﬁcant increase of the TC/HDL-c
ratio, when comparing preplacebo (post-HFC treatment)
and postplacebo in Group A. However, an increase of the
TC/HDL-c ratio is statistically signiﬁcant (P = 0.047) in
Group B without the impact of HFC treatment (Table 7).6 Evidence-Based Complementary and Alternative Medicine
Table 10: Comparison of the LDL-c/HDL-c ratio between pre- and
post-HFC treatment.
Group (No) Pretreatment∗ Posttreatment∗∗
Mean ±SD Mean ±SD
A( n = 14) 2.94 ±0.82 2.81 ±0.71
B( n = 13) 2.94 ±0.87 2.83 ±0.94#
A+B(n = 27) 2.94 ±0.83 2.81 ±0.82##
#P = 0.075; ##P = 0.044.
∗Pretreatment: Group A—pre-HFC treatment; Group B—completed the
ﬁrst four weeks of the placebo intake.
∗∗Posttreatment: Group A completed HFC treatment for the ﬁrst four
weeks; Group B completed HFC treatment for the second four weeks.
Table 11: Comparison of the LDL-c/HDL-c ratio between pre- and
postplacebo intake.
Group (No) Preplacebo intake∗ Postplacebo intake∗∗
Mean ±SD Mean ±SD
A( n = 11) 2.80 ±0.53 2.91 ± 0.60#
B( n = 13) 2.68 ±0.80 2.94 ±0.87##
#P>0.05; ##P = 0.041.
∗Preplacebo intake: Group A completed HFC treatment for the ﬁrst four
weeks and started the placebo intake.
∗∗Postplacebo intake: Group A completed the placebo intake for the second
four weeks; Group B completed the placebo intake for the ﬁrst four weeks.
Table 12: Changes of the blood lipid proﬁle comparing pre- and
post-HFC treatment.
Blood Lipid Group A Group B Group A + B
Total cholesterol (TC) →→ →
Low-density lipoprotein
cholesterol (LDL-c)
→→ →
High-density lipoprotein
cholesterol (HDL-c)
↑→ ↑
The ratio of TC/HDL-c →↓ ↓
The ratio of LDL-c/HDL-c →→ ↓
Triglycerides (TG) →→ →
Note: ↑ = signiﬁcant increase.
→ = no signiﬁcant change.
↓ = signiﬁcant decrease.
This may indicate a “natural” increase of TC in Group B if
no treatment is provided.
3.5. Serum Low-Density Lipoprotein Cholesterol (LDL-c).
ThereisaninsigniﬁcantdiﬀerenceofLDL-clevelscomparing
pre- and post-HFC treatment in Group A, Group B and
o v e r a l lG r o u pA+B( P>0.05) (Table 8).
Again there is an insigniﬁcant increase of the LDL-c level
comparing the pre- and postplacebo intake in both Group A
and Group B (P>0.05), which indicates that the placebo
intake did not have a signiﬁcant impact on the LDL-c level in
this study (Table 9).
3.6. Ratio of LDL-c/HDL-c. Similar to the ratio of TC/HDL-
c, the ratio of LDL-c/HDL-c provides a more informative
marker for CVD risk than the individual value of LDL-c
and HDL-c. There is a decreasing trend of the LDL-c/HDL-c
ratio after the treatment in Group A and Group B (Table 10).
When combining the results from both groups, the decrease
in the LDL-c/HDL-c ratio is statistically signiﬁcant (P =
0.044).
There is an insigniﬁcant increase of LDL-c/HDL-c ratio
comparing posttreatment and postplacebo in Group A.
However, in Group B, without the impact of HFC treatment,
the ratio increased signiﬁcantly after the placebo intake (P =
0.04, Table 11). This may indicate a “natural” increase of
LDL-c/HDL-c ratio in Group B if no treatment is provided.
3.7. General Changes of the Blood Lipid Proﬁle. The results of
the study show possible beneﬁts of HFC on regulating blood
lipid levels. Table 12 summarizes the changes of the blood
lipid levels when comparing pre- and posttreatments in the
two groups.
3.8. Baseline Characteristics of TCM Assessment-Identiﬁcation
of TCM Patterns. The following subjective symptoms were
described by the participants: lower back pain, knee/leg/foot
pain, poor appetite, abdominal discomfort, diarrhoea,
constipation, tiredness, palpitations, insomnia, irritabil-
ity/anxiety/stress, headache, and thirst. The main mani-
festations of the common patterns which may be seen
in patients with dyslipidemia are summarized in Table 13.
The distributions of patterns, major symptoms, signs of
tongue and pulse are summarized in Tables 14, 15, 16,a n d
17. The most prevalent symptoms of the 43 participants
are “abdominal symptoms” (53.5%) “thirst” (51.2%) and
“abnormal bowel movement” (46.5%).
Among the 43 participants who were initially recruited,
the TCM Spleen deﬁciency was found to be predominant
(76.7% of the total). Symptoms and signs which may be rele-
vant to Spleen deﬁciency are prevalent in all the participants.
For example, more than half of the participants complained
of abdominal symptoms before participation; 37.3% of them
had loose stool, diarrhea, or occasional constipation and
diarrhea; 39.5% of them prefer a warm condition to a
cool one. In addition, 48.8% of the participants had teeth
marks on their tongues and more than half had weak
pulse. These signs on the tongue and the pulse are usually
indicative of Spleen deﬁciency. It was found that 58.1% of the
participants were diagnosed of Liver qi stagnation. 55.8% of
the participants complained of stress and 51.2% of them had
wiry pulse, which supports the Liver qi stagnation diagnosis.
4. Discussion
4.1. The Eﬀects on HDL-c. In the present study, the four-
week intake of HFC appears to eﬀectively increase the
serum levels of HDL-c by 5% (Group A + B) for the 27
participants. Compared with the previous clinical study on
this compound [10], which has achieved the +7% increase of
HDL-c, the increase of 5% in the present study is reasonable.
The HDL-c changes are not statistically signiﬁcant when
comparing pre- and postplacebo intakes in both groups,Evidence-Based Complementary and Alternative Medicine 7
Table 13: Major TCM patterns of disharmony and clinical manifestations relating to dyslipidemia.
Patterns Main clinical manifestations
Spleen deﬁciency
Tiredness, preference of warmth, abdominal distension/discomfort, reduced appetite, indigestion, loose
stool/diarrhea (or alternately with constipation), pale or swollen tongue with or without teeth marks, weak
(and/or slippery) pulse
Liver qi stagnation Stress, depression, irritability, anxiety, migraine/dizziness, abdominal distension, oppression in the chest,
irregularity of menstruation, wiry/rough pulse
Kidney deﬁciency
Tiredness, headache/dizziness, insomnia, lower back pain, knee/leg pain, weak pulse in the cubit (chi); yin
deﬁciency with feeling of heat/irritability, thirst, night sweating, thin and red tongue with dry/little coating,
thin and/or rapid pulse; qi and yang deﬁciency with preference of warmth, pale tongue with white coating,
weak pulse (especially in the cubit)
Phlegm and damp
accumulation
Obesity, dizziness, feeling of heavy head and/or body, fullness in the chest and/or abdomen, nausea, bland taste
in the mouth, thirst but without intention to have water, greasy tongue coating, slippery pulse
Blood stasis Dark complexion/lips, encrusted skin, ﬁxed stabbing pain, clots in the menstrual blood with/without
irregularity of menstruation, purple tongue, rough/intermittent/bound pulse
Table 14: Frequencies of baseline TCM patterns of the 43
participants.
TCM patterns∗ Frequency Proportion of the total (%)
Spleen deﬁciency 33 76.7
Liver qi stagnation 25 58.1
Kidney yin deﬁciency 9 20.9
Kidney qi deﬁciency 4 9.3
Phlegm and damp
accumulation 16 37.2
Blood stasis 13 30.2
Food stagnation 6 14.0
Heart heat 14 32.6
Heart qi deﬁciency 5 11.6
Stomach yin deﬁciency 15 34.9
∗Manifestations of diﬀerent TCM patterns may coexist in one individual.
a decreasing trend (5%) has been observed. Because of
limited sample size, further research with more participants
is required.
Epidemiologic studies have demonstrated a high cardio-
vascular risk at low levels of HDL-c regardless of the LDL-
cl e v e l s[ 14]. Substantial atherosclerotic regression (5%
decrease in atheroma volume) occurred only in patients
achieving both low levels of LDL-c (<2.26mmol/L) and an
increase of 7.5% in HDL-c with lipid lowering therapy [15].
According to Ma et al. [16], the component of triter-
penoid acid from hawthorn fruit can enhance the activity
of HDL receptor, which may be a possible mechanism for
the eﬀect on HDL-c. Kiwifruit intake could also contribute
to an increase of HDL-c level in the present study. In a
previous clinical trial, forty-three participants with dyslipi-
demia consumed two kiwifruit per day for eight weeks,
when comparing both pre- and postintervention, the HDL-c
concentration has signiﬁcantly increased [17].
4.2. The Eﬀects on LDL-c, and Ratios of TC/HDL-c and LDL-
c/HDL-c. In this present study, HFC induced a signiﬁcant
decrease of the TC/HDL-c ratio and LDL-c/HDL-c ratio.
Table 15: Frequencies of major baseline symptoms of the 43
participants.
Major symptoms Frequency Proportion of
the total (%)
Preference of warmth 17 39.5
Preference of coolness 9 20.9
Night sweating 5 11.6
Thirst/Dry mouth 22 51.2
Poor appetite 5 11.6
Abdominal symptoms 23 53.5
Abdominal distension 14 32.6
Other discomfort 13 30.2
Reﬂux 11 25.6
Abnormal bowel movement 20 46.5
Loose stool/diarrhea 10 23.3
Constipation 4 9.3
Alternate diarrhea and constipation 6 14.0
Feeling of oppression/occasional
pain in the chest 6 14.0
Palpitation 7 16.3
Feeling stressful/anxiety/depression 24 55.8
Sleep disorder 23 53.5
Feeling sleepy 13 30.2
Dizziness/feeling light-headed 2 4.7
Headache 11 25.6
Lower back/leg/knee pain 16 37.2
However, no signiﬁcant eﬀects on serum TC, LDL-c, and TG
were found. Such outcomes are consistent with the previous
study [17].
Although the LDL-c is considered as the primary
treatment target for lipid management [3, 18], the CVD-
predictingpowerofTC/HDL-cratioandLDL-c/HDL-cratio
has been investigated extensively. A meta-analysis of 61
observational studies has shown that the TC/HDL-c ratio
is substantially more informative as a predictor of CHD8 Evidence-Based Complementary and Alternative Medicine
Table 16: Tongue features of the 43 participants.
Tongue feature Frequency Proportion of the total (%)
Tongue body color
Pink 6 14.0
Pale 12 27.9
Red 6 14.0
Purple 14 32.6
Red tip 15 34.9
Tongue body
Normal 13 34.9
Swollen 6 14.0
Thin 22 51.2
With teeth marks 21 48.8
Without teeth marks 22 51.2
Coating texture
Thin 7 16.3
Thick/greasy 9 20.9
Dry 6 14.0
Less than normal 3 7.0
Fissure 19 44.2
Coating color
White 28 65.1
Yellow 15 34.9
Table 17: Pulse features of the 43 participants.
Pulse feature Frequency Proportion of the total (%)
Rate
Normal 33 76.7
Slow 1 2.3
Fast 6 14.0
Uneven 2 4.6
Left pulse
Slippery 15 34.9
Thin 15 34.9
Soft/weak 23 53.5
Wiry 22 51.2
Right pulse
Slippery 18 41.9
Thin 19 44.2
Soft/Weak 25 58.1
Wiry 15 34.9
mortality than the individual value of TC, HDL-c, or non-
HDL-c [11]. In a post hoc study with 9770 participants,
it was indicated that the LDL-c/HDL-c ratio was highly
predictive of major cardiovascular events [14].
Another relevant study showed that HFC signiﬁcantly
reduced serum levels of LDL-c, TG, and the LDL-c/HDL-c
ratio in atherosclerotic mice, and this eﬀect was comparable
with the control of statins therapy [19].
In the previous clinical study conducted by Chen et al.
[10], the HFC drink was taken by 60 Chinese participants for
31 days. The resultsshowed that the supplement signiﬁcantly
improved the whole blood lipid proﬁle, including reducing
TC (−10%), TG (−12%), LDL-c (−18%), and increasing
HDL-c (+7%). Statistically, the design and results of the
previous study was used to predict the statistical power
of the present study. The power calculation indicated that
62 participants were needed to achieve overall statistically
signiﬁcant outcomes. The insigniﬁcant results of LDL-c and
TG levels in this study may be due to the low number of
participants.
4.3. Impacts of Genetic, Ethnical, Cultural, and Lifestyle-
Related Factors. In the present study, the Australian par-
ticipants originated from more than 10 countries or areas
(not including East Asia), which reﬂects the fact of the
composition of Melbourne population, however, this may
also aﬀect the research outcomes because of the diversity of
genetic factors and culture-related lifestyles. Classiﬁcation of
participants by diﬀerent lipoprotein subgroups or relevant
genotypes was unavailable. It is diﬃcult to determine
whethertherewasadetectablediet-geneinteractioninvolved
in the study or not. In the case of disparities of blood lipid
level and CVD risk, evidence on their relationships with
ethnic features is not convincing.
In Chen et al. study [10], the HFC drink signiﬁcantly
increased the serum levels of apoA—I and superoxide
dismutase (SOD), and decreased the levels of apoB and
malondialdehyde (MDA) in the Chinese participants. Such
results show the additional favorable eﬀects of HFC on
cardiovascular health. The serum apoB level represents the
total atherogenic property of blood lipids, and the apoA—
I level reﬂects the antiatherogenic property. The MDA
and SOD levels indicate the body’s oxidative status and
antioxidative ability, respectively. Further study with other
biomedical parameters is of beneﬁt to investigate the eﬀects
of HFC.
4.4. Baseline Characteristics of TCM Assessment. The above
TCM ﬁndings are consistent with previous research in which
Spleen deﬁciency and Liver qi stagnation were recognized
as major root causes of abnormal blood lipid metabolism
[20, 21]. This may indicate that high-level stress and reduced
digestion associate with the occurrence of dyslipidemia.
T h es a m ep a t t e r nw a sf o u n di nA u s t r a l i a nw o m e nw i t h
premenstrual syndromes [22]. However, because the data of
TCMpatternprevalenceingeneralAustralianpopulationare
unavailable, it is diﬃcult to determine whether the pattern
features observed in this study is speciﬁc for the whole
cohort with moderate dyslipidemia or not. Studies on TCM
pattern prevalence in Australian population are needed and
the results can be used as a reference for outcome evaluation
of the TCM clinical trials.
Long-term or severe dyslipidemia have also been viewed
as a condition or pattern of blood and phlegm stagnation in
TCM. It is noted that 32.6% of the participants have the
purple tongue body, a typical sign indicating blood stasis.Evidence-Based Complementary and Alternative Medicine 9
However, the prevalence of phlegm and blood stagnation
pattern is not as high compared to Spleen deﬁciency in
the participants with moderate dyslipidemia. Therefore, the
pattern of blood and phlegm stagnation may need to be
identiﬁed in severe dyslipidemia cases.
Another ﬁnding of this study is that many participants
had heat-related symptoms and signs, that is, 51.2% of the
participants complained of thirst or dry mouth, 34.9% with
red tongue tip or yellow tongue coating, and 44.2% with
tonguecoatingﬁssure.Thisheat patternwasalsoreportedby
Fu and Xu [23] in their study on Australian peri-menopausal
women. Although Spleen deﬁciency may also result in thirst
as the ﬂuid cannot be transformed suﬃciently and be trans-
ported upward to nourish the mouth, about one third of the
participantswerediagnosedofHeart heat patternorStomach
yin deﬁciency pattern, respectively. Heat patterns in patients
with dyslipidemia have not been emphasized in previous
TCM research. Possible TCM mechanisms may involve the
qi stagnation and phlegm accumulation which can generate
heat, resembling the heat-generating process of compost; the
heat mayinturndeterioratelipidmetabolismbyoverheating
ﬂuid intothethickandpathologicalphlegm.Accordingtothe
TCM theory, kiwifruit, with the cool nature, can remove heat
and nourish yin [24]. Thus, the consumption of kiwifruit
can be beneﬁcial for people with heat patterns. Further study
is needed to explore the optimized the TCM treatment for
people with dyslipidemia and heat pattern. The utilization of
Chinese therapeutic food according to the TCM diﬀerential
diagnosis can be explored as a tailored treatment of diet-
related conditions.
5. Conclusion
Intake of the Chinese therapeutic food, speciﬁcally the
hawthorn fruit compound, has shown a positive eﬀect on
increasing serum HDL-c levels and decreasing ratios of
TC/HDL-c and LDL-c/HDL-c, which indicates an improve-
ment of the blood lipid proﬁle. As a dietary therapy, this
compound can be considered for the treatment of hyper-
lipidemia and the prevention of atherosclerosis, and such
eﬀects need to be further explored. The major TCM patterns
observed in this moderately dyslipidemic participants’ group
include “Spleen deﬁciency” and “Liver qi stagnation.”
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